A new Inserm Transfert Technology Offers experience coming soon in April !

BIO10412-T1

Recombinant flagellin for preventing and treating respiratoryinfections / COPD-AE

The present invention relates to the use of an optimized truncated flagellin (TLR5 agonist devoided of toxic effect) for preventing or treating respiratory tract infection. Both preventive and currative effects in the absence of any antibiotic have been demonstrated in […]

BIO13024-T1

M-CSF for preventing or treating myeloid cytopenia and related complications following hematopoetic stem cell transplantation

The invention relates to a method for preventing or treating myeloid cytopenia and related complications such as infections in patients undergoing hematopoietic stem cell transplantation (HSCT). The approach is based on the priming of the hematopoietic stem cell graft with […]

BIO12320-T1

Fonctionalized microparticules as vaccination adjuvant and Ag vector for the development of therapeutic vaccines against cancer

The invention relates to microparticules fonctionalized with alphagalactosylceramide for sustained iNKT cell activation. Delivering of alphagalactosylceramide (a natural iNKT agonist presented by DC to iNKT cells) through functionalized microparticules allows to prevent the iNKT anergy observed with non vectorized alphagalactosylceramide. […]

BIO11035-T1

GABA Administration Induces Alpha Cell-Mediated Beta-like Cell Neogenesis

GABA is an inducer of α-to-β-like cell conversion in vivo. This conversion induces α cell replacement mechanisms through the mobilization of duct-lining precursor cells that adopt an α cell identity prior to being converted into β-like cells, solely upon sustained […]

BIO17636-T1

USE OF TRIETHYLENETETRAMINE (TETA) FOR THE THERAPEUTIC INDUCTION OF AUTOPHAGY

Autophagy is a universal anti-aging mechanism the chronic induction of which can extend the health span and lifespan of mammals. Here the inventors show that triethylenetetramine (TETA), also called trientine, a drug that is approved for the treatment of Wilson […]

BIO14138-T1

Anti-Cathepsin D human antibody for Triple Negative Breast Cancer Treatment

Inventors have generated two human anti-cath-D scFv fragments cloned in the human IgG1 format (F1 and E2) that efficiently bind to human and mouse cath-D, even at the acidic pH of the TNBC microenvironment. F1 and E2 accumulated in TNBC […]

BIO15365-T1

Anti-Nectin-4 monoclonal antibodies

The present invention relates to a new antibody anti-nectin-4. Nectin-4 is a tumor-associated antigen overexpressed in several cancers and notably in 30%, 49% and 86% of breast, ovarian and lung carcinomas, respectively, which are tumors of bad prognosis. Treatments remain […]

BIO14015-T1

Anti-Neurotensin mAb for the treatment of cancer

The present invention relates to a neutralising antibody which is capable of binding to neurotensin with high affinity. The antibody of the present invention neutralises the activity of neurotensin, in particular the oncogenic activities of neurotensin. In particular, the present […]

BIO14361-T1

HUMAN MONOCLONAL ANTIBODIES AGAINST OREXIN RECEPTOR TYPE 1

The present invention relates to human monoclonal antibodies against orexin receptor type 1 (OX1R) and uses thereof for the treatment of cancer.

BIO07104-T1

Gene therapy approach combined to chemotherapy for improving treatment of cancer

The present invention concerns products containing (i) at least one nucleic acid sequence coding for the human somatostatin 2 receptor protein (sst2), (ii) at least one nucleic acid sequence coding for the human deoxycytidine kinase protein (dck), (iii) at least […]

12 Last patents posted


The 10 Last viewed

You haven't seen any form yet.